Boehringer Ingelheim drug Micardis receives positive recommendation

Boehringer Ingelheim has revealed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency has issued a positive opinion for the approval of Micardis (telmisartan) for the reduction of cardiovascular (CV) morbidity.

This applies to patients suffering from either manifest atherothrombotic cardiovascular disease or type 2 diabetes mellitus with documented target organ damage.

According to the firm, Micardis could offer a much-needed alternative to ACE inhibitors in the treatment of patients with high CV risk.

“We are delighted to receive this positive opinion from the CHMP. This is an important development that will help physicians ensure that patients receive appropriate treatment tailored to their individual needs,” explained Professor Klaus Dugi, corporate vice-president of medical affairs at Boehringer Ingelheim.

This news comes after the Food and Drug Administration approved Micardis for use in patients at high risk of cardiovascular incidents.